Ajax therapeutics raises $95 million series c financing to advance first-in-class type ii jak2 inhibitor, aj1-11095, into the clinic

New york & cambridge, mass.--(business wire)--ajax therapeutics, inc., a biopharmaceutical company developing next generation jak inhibitors for patients with myeloproliferative neoplasms (mpns), today announced the closing of an oversubscribed $95 million series c financing. proceeds from the financing will be used to support the clinical development of ajax's first-in-class type ii jak2 inhibitor, aj1‑11095, for the treatment of myelofibrosis, as well as advancing the company's pipeline of tr.
GS Ratings Summary
GS Quant Ranking